World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
98
Citations
46954
World Ranking
8783
National Ranking
4527

Overview

Bradley J. Monk is affiliated with the University of Arizona in the United States. Their research focuses primarily on medicine, with a strong emphasis on oncology, reproductive medicine, and obstetrics and gynecology. Additional subfields of study include pulmonary and respiratory medicine as well as surgery.

The scientist's main research topics include:

  • Ovarian cancer diagnosis and treatment
  • Endometrial and cervical cancer treatments
  • PARP inhibition in cancer therapy
  • Cancer immunotherapy and biomarkers
  • Cervical cancer and HPV research
  • Cancer genomics and diagnostics
  • Lung cancer treatments and mutations

Bradley J. Monk has contributed to a variety of journals and publication venues, with the most frequent being:

  • Gynecologic Oncology
  • Journal of Clinical Oncology
  • International Journal of Gynecological Cancer
  • Annals of Oncology
  • The Lancet Oncology

Their recent notable papers include:

  • Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer, 2021, New England Journal of Medicine
  • Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer, 2023, New England Journal of Medicine
  • Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study, 2021, The Lancet Oncology
  • Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study, 2021, The Lancet Oncology
  • A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45), 2022, Journal of Clinical Oncology

Throughout their career, the scientist has frequently collaborated with several colleagues, including:

  • Robert L. Coleman
  • David M. O'Malley
  • Krishnansu S. Tewari
  • Kathleen N. Moore
  • Domenica Lorusso

Best Publications

  • Incorporation of bevacizumab in the primary treatment of ovarian cancer

    Robert A. Burger;Mark F. Brady;Michael A. Bookman;Gini F. Fleming

  • Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

    Mansoor R. Mirza;Bradley J. Monk;Jørn Herrstedt;Amit M. Oza

  • Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

    Antonio González-Martín;Bhavana Pothuri;Ignace Vergote;René DePont Christensen

  • Improved Survival with Bevacizumab in Advanced Cervical Cancer

    Krishnansu S. Tewari;Michael W. Sill;Harry J. Long;Richard T. Penson

  • Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Antonio González-Martín;Bhavana Pothuri;Ignace Vergote;René De Pont Christensen

  • Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study

    Robert A. Burger;Michael W. Sill;Bradley J. Monk;Benjamin E. Greer

  • Carcinogenic human papillomavirus infection.

    Mark Schiffman;John Doorbar;Nicolas Wentzensen;Silvia de Sanjosé

  • Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer

    John B. Welsh;Patrick P. Zarrinkar;Lisa M. Sapinoso;Suzanne G. Kern

  • Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study

    Bradley J. Monk;Michael W. Sill;D. Scott McMeekin;David E. Cohn

  • Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

    Nicoletta Colombo;Coraline Dubot;Domenica Lorusso;M Valeria Caceres

  • Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients With Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial

    Maurie Markman;P.Y. Liu;Sharon Wilczynski;Bradley Monk

  • Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

    Krishnansu S. Tewari;Michael W. Sill;Richard T. Penson;Helen Huang

  • Latest research and treatment of advanced-stage epithelial ovarian cancer

    Robert L. Coleman;Bradley J. Monk;Anil K. Sood;Thomas J. Herzog

  • Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

    Bradley J. Monk;Thomas J. Herzog;Stanley B. Kaye;Carolyn N. Krasner

  • Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

    Kathleen N Moore;Angeles Alvarez Secord;Melissa A Geller;David Scott Miller

  • Adhesions after extensive gynecologic surgery: Clinical significance, etiology, and prevention * ** *

    Bradley J. Monk;Michael L. Berman;F.J. Montz

  • Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study

    Bradley J. Monk;Michael W. Sill;Robert A. Burger;Heidi J. Gray

  • Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

    John K. Chan;Mark F. Brady;Richard T. Penson;Helen Huang

  • Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer

    Andreas Du Bois;Anne Floquet;Jae Weon Kim;Jae Weon Kim;Joern Rau

  • Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer

    Krishnansu S. Tewari;Robert A. Burger;Danielle Enserro;Barbara M. Norquist

Frequent Co-Authors

Thomas J. Herzog
Thomas J. Herzog University of Cincinnati
Robert L. Coleman
Robert L. Coleman The University of Texas MD Anderson Cancer Center
David M. O'Malley
David M. O'Malley The Ohio State University
Kathleen N. Moore
Kathleen N. Moore University of Oklahoma Health Sciences Center
Ana Oaknin
Ana Oaknin Vall d'Hebron Hospital Universitari
Amit M. Oza
Amit M. Oza Princess Margaret Cancer Centre
Nicoletta Colombo
Nicoletta Colombo University of Milano-Bicocca
Michael J. Birrer
Michael J. Birrer University of Arkansas for Medical Sciences
Robert S. Mannel
Robert S. Mannel University of Oklahoma Health Sciences Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a medical career in the USA doesn’t always mean following the traditional route to become a doctor. Many students consider related fields that offer rewarding, impactful opportunities with flexible online learning options. Programs such as adn programs (Associate Degree in Nursing) provide a practical pathway to becoming a registered nurse in less time than a full bachelor’s degree.

Those interested in administrative roles can benefit from accelerated healthcare programs offered online, helping you enter the workforce quickly. Additionally, online medical coding classes with financial aid can open doors to essential roles in the growing field of healthcare information management, with minimal upfront costs.

For those seeking less competitive entry requirements, there are nursing schools that don't require teas or hesi exams, reducing barriers to admission and attracting a wider range of applicants. These options highlight how students can pursue diverse, valuable healthcare careers through accessible and flexible education paths beyond medical school.

Best Scientists Citing Bradley J. Monk

Trending Scientists